4SC Discovery, Crelux and Ribological Launch Collaboration
Complete the form below to unlock access to ALL audio articles.
4SC AG has announced that its subsidiary 4SC Discovery GmbH, which specializes in the discovery and early-stage research of novel therapeutic compounds, has agreed a research collaboration with Ribological GmbH, Mainz, in the area of compound screening.
The aim of the research project is to identify and optimize new and more effective anti-cancer compounds.
4SC Discovery and Crelux GmbH, its strategic partner for services in the field of biopharmaceutical early-stage research, have been commissioned by Ribological to implement a hit finding programme to identify and optimize potential new small molecule compounds that are expected to have a synergistic effect with the RNA molecules used by Ribological in cancer immunotherapy.
Ribological intends to carry out preclinical testing of the compounds and, if successful, develop these further in clinical trials in combination with its RNA-based drugs.
In detail, 4SC Discovery is using its patented IT-aided in silico screening process to perform calculations of the properties of several million substances with the goal of identifying the best possible drug candidates.
This is intended to accelerate the development process for early-stage compound research and achieve greater cost efficiency than conventional approaches.
Crelux, 4SC Discovery's research partner that specializes in research services in the field of proteins, especially protein production and crystallization, is performing the associated molecular-biological tests for optimizing the compounds in INTRACT-MST assays.
The partnership will generate revenue that could reach the low six-figure euro range for each 4SC Discovery and Crelux.
Dr. Daniel Vitt, Managing Director of 4SC Discovery GmbH and Chief Scientific Officer at 4SC AG, comments: 'We are delighted to have secured Ribological as a cooperation partner for our drug discovery activities - a company with a strong research track record and a highly innovative approach in cancer medicine. This is also the first major joint project that we have launched as part of our new strategic i2c (idea to candidate) cooperation with our partner Crelux. As service providers and cooperation partners for biotech and pharma companies, 4SC Discovery and Crelux together can cover both the entire value chain from the idea for a product to the preclinical drug development candidate and also supplement it as needed.'
Prof. Dr. Ugur Sahin, Managing Director of Ribological GmbH, comments: 'In 4SC Discovery GmbH we have won an expert and, simultaneously, an exceedingly pleasant cooperation partner for small molecule compound screening. We expect this to be a high-level synergistic collaboration.'
